Silo Pharma, Inc.

Silo Pharma Inc. is a developmental stage biopharmaceutical and cryptocurrency company. Its therapeutics focus is on developing novel treatments for underserved conditions such as PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. The company develops both conventional drugs and psychedelic formulations. Silo Pharma's lead program, SPC-15, is an intranasal drug designed to target PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-based loaded implant intended for fibromyalgia and chronic pain relief. The company also has two preclinical programs: SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting the central nervous system with initial research indication in multiple sclerosis (MS). Silo Pharma seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs like psilocybin and ketamine. The company concentrates on the development and commercialization of therapies for unmet needs from indications such as depression, post-traumatic stress disorder ("PTSD"), and other rare neurological disorders. Psilocybin is a serotonergic hallucinogen and an active ingredient in some mushroom species. While classified as a Schedule I substance under the Controlled Substances Act ("CSA"), the U.S. Food and Drug Administration ("FDA") and U.S. Drug Enforcement Agency ("DEA") have permitted its use in clinical studies for a range of psychiatric conditions.